Pesquisar
Pharvaris NV
PHVSAdicionar à lista de desejos
33.950USD
-0.630-1.82%
Fechamento 07/01, 16:00（ET）Cotações atrasadas em 15 min
2.37BValor de mercado
PerdaP/L TTM
Mais detalhes de Pharvaris NV Empresa
Pharvaris NV is a Netherlands-based company primarily engaged in the biopharmaceutical industry. The Company focuses on developing oral bradykinin B2 receptor antagonists to treat and prevent hereditary angioedema (HAE) attacks. Their key product is Deucrictibant (PHA121, PHA-022121), which is a small-molecule bradykinin B2 receptor antagonist. It is intended for both the on-demand and prophylactic treatment of HAE attacks. Deucrictibant has been studied in vitro, ex vivo, and in vivo models to assess its effectiveness in blocking the bradykinin B2 receptor. The Company is developing deucrictibant for on-demand use as PHVS416, a softgel capsule, and for prophylactic use as PHVS719, an extended-release tablet.
Informações de Pharvaris NV
Código da empresaPHVS
Nome da EmpresaPharvaris NV
Data de listagemFeb 05, 2021
CEOModig (Berndt B.A.E)
Número de funcionários- -
Tipo de títulosOrdinary Share
Fim do ano fiscalFeb 05
EndereçoEmmy Noetherweg 2
CidadeLEIDEN
Bolsa de valoresNASDAQ OMX - NASDAQ BASIC
PaísNetherlands
Código postal2333 BK
Telefone31712036410
Sitehttps://pharvaris.com/
Código da empresaPHVS
Data de listagemFeb 05, 2021
CEOModig (Berndt B.A.E)
Executivos da empresa Pharvaris NV
Nome
Nome/Posição
Posição
Ações detidas
Variação
Mr. Berndt Modig, CPA
Mr. Berndt Modig, CPA
Chief Executive Officer, Co-Founder, Executive Director
Chief Executive Officer, Co-Founder, Executive Director
1.63M
-0.14%
Dr. Peng Lu, M.D., Ph.D.
Dr. Peng Lu, M.D., Ph.D.
Chief Medical Officer
Chief Medical Officer
505.39K
-0.04%
Mr. David W. Nassif, J.D.
Mr. David W. Nassif, J.D.
Chief Financial Officer
Chief Financial Officer
191.62K
-5.22%
Dr. David P. Meeker ,M.D.
Dr. David P. Meeker ,M.D.
Non-Executive Director
Non-Executive Director
152.35K
+32.51%
Dr. Elisabeth Bjork, M.D., Ph.D.
Dr. Elisabeth Bjork, M.D., Ph.D.
Non-Executive Director
Non-Executive Director
110.78K
--
Ms. Viviane Monges
Ms. Viviane Monges
Non-Executive Director
Non-Executive Director
96.45K
-10.02%
Ms. Anna Nijdam
Ms. Anna Nijdam
Head of Finance, Principal Accounting Officer
Head of Finance, Principal Accounting Officer
47.61K
-5.61%
Dr. Jochen Knolle, Ph.D.
Dr. Jochen Knolle, Ph.D.
Co-Founder, Chief Operating Officer, Chief Scientific Officer
Co-Founder, Chief Operating Officer, Chief Scientific Officer
--
--
Dr. Anne Lesage, Ph.D.
Dr. Anne Lesage, Ph.D.
Co-Founder, Chief Early Development Officer
Co-Founder, Chief Early Development Officer
--
--
Dr. Morgan Conn, Ph.D.
Dr. Morgan Conn, Ph.D.
Chief Business Officer
Chief Business Officer
--
--
Ver Mais
Nome
Nome/Posição
Posição
Ações detidas
Variação
Mr. Berndt Modig, CPA
Mr. Berndt Modig, CPA
Chief Executive Officer, Co-Founder, Executive Director
Chief Executive Officer, Co-Founder, Executive Director
1.63M
-0.14%
Dr. Peng Lu, M.D., Ph.D.
Dr. Peng Lu, M.D., Ph.D.
Chief Medical Officer
Chief Medical Officer
505.39K
-0.04%
Mr. David W. Nassif, J.D.
Mr. David W. Nassif, J.D.
Chief Financial Officer
Chief Financial Officer
191.62K
-5.22%
Dr. David P. Meeker ,M.D.
Dr. David P. Meeker ,M.D.
Non-Executive Director
Non-Executive Director
152.35K
+32.51%
Dr. Elisabeth Bjork, M.D., Ph.D.
Dr. Elisabeth Bjork, M.D., Ph.D.
Non-Executive Director
Non-Executive Director
110.78K
--
Ms. Viviane Monges
Ms. Viviane Monges
Non-Executive Director
Non-Executive Director
96.45K
-10.02%
Perguntas frequentes
Quem são os cinco principais acionistas de Pharvaris NV?
Os cinco principais acionistas de Pharvaris NV são: Mr. Berndt Modig, CPA
Quantas instituições possuem ações da Pharvaris NV (PHVS)?
Em 2026Q1, 165 instituições possuíam ações da Pharvaris NV, com valor de mercado aproximado de 59.26M, representando 90.60% do total de ações. Em comparação com 2025Q4, a participação institucional aumentou em -451327.00.